The development of organ-conserving treatment for locally advanced head and neck cancers shifted the paradigm for treatment. A decade ago, we developed the strategy of selecting patients for chemoradiotherapy or for laryngectomy based on their response to a single cycle of chemotherapy. This approach results in 3-year cause-specific survival and laryngeal preservation rates of 87% and 70%, respectively. However, chemoradiation is associated with an increased rate of mucositis and dysphagia compared with radiotherapy alone. The long-term goal of this application is to preserve a high rate of larynx preservation while decreasing the toxicity of treatment by using cetuximab-radiation instead of chemoradiotherapy in patients selected to benefit from this approach. These goals will be achieved through 3 specific aims.
Specific Aim 1 is to decrease the toxicity of larynx-preserving treatment by using cetuximab-radiation in place of chemoradiation in appropriately selected patients.
In Aim 1 A we propose to extend our current strategy in a phase II study of cetuximab-radiation for patients who would previously have received chemoradiation: those responding to a cycle of chemotherapy.
In Aim 1 B, we propose to assess tumor biopsies in the patients who respond to a cycle of chemotherapy and then receive cetuximab for markers of EGFR activation and downstream inhibition as possible predictors of response to cetuximab-radiation.
Specific Aim 2 is to investigate the potential of established markers (Aim 2A) and to discover potential new biomarkers (Aim 2B) by assessment of phosphoproteome to predict response to cetuximab combined with radiation. Our preliminary data suggest that the extent and duration of decrease in the established markers like total EGFR, pEGFR, pSTATS, Bcl-XL, and Ki67 correlate with response to the combination of EGFR inhibitors and radiation. In this aim, we propose to extend these studies to a total of 20 head and neck xenografts, 10 responsive and 10 non-responsive.
In Aim 2 B we will assess the effects of cetuximab-radiation on phosphoproteins using proteomic technology. Our preliminary data indicate that this is a promising method of identifying novel phosphoproteins that are affected by cetuximab treatment.
Specific Aim 3 is to carry out preclinical studies to improve the efficacy of EGFR inhibition with radiochemotherapy.
In Aim 3 A, we focus on the potential importance of schedule for combining EGFR inhibition with radiochemotherapy.
In Aim 3 B we will focus on a novel approach toward targeting EGFR via HSP90 inhibition. Our preliminary data show that geldanamycin, an inhibitor of HSP90, accelerates the degradation of EGFR in cisplatin resistant cells, leading to both cellular toxicity and radiosensitization. We feel our preclinical and clinical team with an extensive track record in this field makes it likely that these studies will improve patient outcome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097248-10
Application #
8382514
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$192,728
Indirect Cost
$87,645
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Arthur, Anna E; Goss, Amy M; Demark-Wahnefried, Wendy et al. (2018) Higher carbohydrate intake is associated with increased risk of all-cause and disease-specific mortality in head and neck cancer patients: results from a prospective cohort study. Int J Cancer 143:1105-1113
Akkina, Sarah R; Kim, Roderick Y; Stucken, Chaz L et al. (2018) Is There a Difference in Staging and Treatment of Head and Neck Squamous Cell Tumors Between Tertiary Care and Community-Based Institutions? Laryngoscope Investig Otolaryngol 3:290-295
VanKoevering, Kyle K; Marchiano, Emily; Walline, Heather M et al. (2018) An Algorithm to Evaluate Suspected Lung Metastases in Patients with HPV-Associated Oropharyngeal Cancer. Otolaryngol Head Neck Surg 158:118-121
Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97
Koneva, Lada A; Zhang, Yanxiao; Virani, Shama et al. (2018) HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. Mol Cancer Res 16:90-102
Yokosawa, Eva B; Arthur, Anna E; Rentschler, Katie M et al. (2018) Vitamin D intake and survival and recurrence in head and neck cancer patients. Laryngoscope 128:E371-E376
Tan, Yee Sun; Sansanaphongpricha, Kanokwan; Xie, Yuying et al. (2018) Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. Clin Cancer Res 24:4242-4255
Udager, A M; McHugh, J B; Goudsmit, C M et al. (2018) Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas. Ann Oncol 29:466-471
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
Pinatti, L M; Walline, H M; Carey, T E (2018) Human Papillomavirus Genome Integration and Head and Neck Cancer. J Dent Res 97:691-700

Showing the most recent 10 out of 260 publications